Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

NCT06504966 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision not to proceed with the study.

Conditions

Osteoporosis

Interventions

DRUG: MAB-22
DRUG: Prolia®

Sponsor

Xentria, Inc.